Petersen K G, Khalaf A, Zeisel H J, Stryjek-Kaminska D, Kerp L
Department of Clinical Endocrinology, University Medical Hospital, Freiburg, FRG.
Acta Endocrinol (Copenh). 1989 Oct;121(4):501-4. doi: 10.1530/acta.0.1210501.
Clinical manifestations of allergy to biosynthetic hGH were not reported in 245 patients treated for one year. A sensitive radioallergosorbent test showed, however, the presence of anti-hGH IgE antibodies in the sera of 13%. All patients with anti-hGH IgE had also elevated concentrations of total serum IgE, similar to atopic persons (2459 +/- 147 micrograms/l, normal 70 +/- 8, 2p less than 0.0001); 83% of all patients who had specific IgE antibodies to hGH had specific antibodies prior to treatment. Administration of hGH did not consistently change concentrations (up to 8 micrograms/l) or affinities (less than 10(7) to 1.3 X 10(9) l/mol) of the specific reagins. Anti-hGH IgE antibodies were related to atopy. Treatment with biosynthetic hGH did not significantly stimulate specific IgE.
在接受一年治疗的245名患者中,未报告对生物合成人生长激素(hGH)过敏的临床表现。然而,一项灵敏的放射变应原吸附试验显示,13%的患者血清中存在抗hGH IgE抗体。所有抗hGH IgE的患者血清总IgE浓度也升高,类似于特应性个体(2459±147微克/升,正常为70±8,P<0.0001);所有对hGH有特异性IgE抗体的患者中,83%在治疗前就有特异性抗体。给予hGH并未持续改变特异性反应素的浓度(高达8微克/升)或亲和力(10^7至1.3×10^9升/摩尔)。抗hGH IgE抗体与特应性有关。生物合成hGH治疗并未显著刺激特异性IgE。